FDA approves oral semaglutide first GLP-1 pill

The U.S. Food and Drug Administration approved Novo Nordisk's once-daily Wegovy pill on December 22, 2025, giving the company the first oral GLP-1 medicine cleared in the United States for chronic weight management. The approval covers adults with obesity and adults who are overweight and have at least one weight-related condition, according to the FDA approval letter and prescribing information. (accessdata.fda.gov) The label also includes a cardiovascular indication for reducing the risk of major adverse events in adults with established cardiovascular disease and either obesity or overweight. (biospace.com) Novo Nordisk said it planned a U.S. launch in early January 2026. ### What exactly did the FDA clear? The FDA approval letter says Wegovy tablets are to be used with a reduced-calorie diet and increased physical activity. (biospace.com) The drug is approved to reduce excess body weight and maintain long-term weight reduction in adults with obesity, or adults with overweight who have at least one weight-related comorbidity. The prescribing information also says Wegovy tablets are indicated to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight. That aligns the pill with a broader Wegovy brand label that already included cardiovascular risk reduction. (accessdata.fda.gov) ### How is this different from the semaglutide pills already on the market? Semaglutide was already available orally before this decision, but not for weight management. Novo Nordisk's U.S. site says Ozempic pill is an FDA-approved oral peptide GLP-1 for adults with type 2 diabetes, while the newly approved Wegovy pill is the first oral GLP-1 specifically cleared for obesity or overweight with related medical problems. (accessdata.fda.gov) The distinction matters because the new approval puts a pill form directly into the U.S. obesity market that has been dominated by injections. AJMC reported that the once-daily oral semaglutide product is positioned as a non-injectable alternative to weekly GLP-1 shots. (accessdata.fda.gov) ### What evidence did Novo Nordisk use to win approval? Novo Nordisk said the approval was based on the OASIS clinical program and the SELECT cardiovascular outcomes trial. The key weight-loss evidence came from OASIS 4, a 64-week phase 3 study in 307 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. (novonordisk-us.com) In OASIS 4, AJMC reported that patients taking oral semaglutide posted a mean body-weight reduction of 13.6% at week 64, compared with 2.2% for placebo. Novo Nordisk separately said that, under an analysis assuming patients stayed on treatment, average weight loss was 16.6% versus 2.7% for placebo. (ajmc.com) ### What did the company say about access and launch timing? Dave Moore, executive vice president of U.S. operations at Novo Nordisk, said in the company's announcement that manufacturing was underway in North Carolina and that the company was prepared for a full U.S. launch in early January 2026. He said the pill would offer "the most affordable self-pay price to date" in a GLP-1 for obesity, though the company statement cited by BioSpace did not provide a full list price for the maintenance dose in the lines reviewed. (biospace.com) Mike Doustdar, then president and chief executive of Novo Nordisk, said in a statement carried by AJMC that the pill would give patients a once-daily option that could help them lose as much weight as the original Wegovy injection. (biospace.com) AJMC said the approved oral dose was 25 mg. ### What safety warnings remain on the label? The FDA prescribing information for Wegovy tablets carries a boxed warning on thyroid C-cell tumors. The label says semaglutide caused thyroid C-cell tumors in rodents and that it is unknown whether Wegovy causes such tumors in humans. The same label says Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. (biospace.com) AJMC reported that most adverse events in OASIS 4 were mild or moderate. ### What comes next for the pill? Novo Nordisk said in December 2025 that U.S. availability would begin in early January 2026. (ajmc.com) The FDA approval letter also required the company to submit final labeling materials within specified post-approval deadlines, including structured product labeling as soon as possible and no later than 14 days after the letter. (accessdata.fda.gov 1) (accessdata.fda.gov 2)